(Q38131232)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23973345%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

Group B streptococcal epidemiology and vaccine needs in developed countries (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23973345%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23973345%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Androulla Efstratiou

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23973345%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

language of work or name

English

0 references

publication date

1 August 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23973345%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23973345%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

31 Suppl 4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23973345%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

D31-42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23973345%20AND%20SRC:MED&resulttype=core&format=json

Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis

8 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

7 January 2021

Group B streptococcus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Evaluation of Universal Antenatal Screening for Group B Streptococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Group B streptococcal disease in infants: progress in prevention and continued challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Epidemiology of Invasive Group B Streptococcal Disease in the United States, 1999-2005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Ten-year study on the effect of intrapartum antibiotic prophylaxis on early onset group B streptococcal and Escherichia coli neonatal sepsis in Australasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Rapid detection of group B streptococci in pregnant women at delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Perinatal group B streptococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Invasive group B streptococcal infections in infants, France

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Revisiting the Need for Vaccine Prevention of Late-Onset Neonatal Group B Streptococcal Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Molecular and phenotypic characterization of invasive group B streptococcus strains from infants in Norway 2006-2007.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Group B streptococcal infections in a northern region of Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Increasing Burden of Invasive Group B Streptococcal Disease in Nonpregnant Adults, 1990–2007

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Group B streptococcal beta-hemolysin promotes injury of lung microvascular endothelial cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Granadaene: proposed structure of the group B Streptococcus polyenic pigment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Identification of group B streptococcal Sip protein, which elicits cross-protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Genome Analysis Reveals Pili in Group B Streptococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Pili in gram-positive pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Genomic organization, structure, regulation and pathogenic role of pilus constituents in major pathogenic Streptococci and Enterococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Induction and termination of inflammatory signaling in group B streptococcal sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Maternal carriage of group B streptococci in developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Intrauterina infections with group B beta-haemolytic streptococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Epidemiology of the group B streptococcus: Maternal and nosocomial sources for infant acquisitions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Evaluation of intrapartum antibiotic prophylaxis for the prevention of early-onset group B streptococcal infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Prevention of early-onset neonatal group B streptococcal disease with selective intrapartum chemoprophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Group B streptococcal carriage and disease: a 6-year prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Early-onset neonatal group B streptococcal septicaemia in siblings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Obstetrical care in future pregnancies after fetal loss in group B streptococcal septicemia. A prevention program based on bacteriological and immunological follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Neonatal septicemia due to group B streptococci--perinatal risk factors and outcome of subsequent pregnancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Breast milk as a source of late onset neonatal sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Infected breast milk associated with late-onset and recurrent group B streptococcal infection in neonatal twins: a genetic analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Prevention of group B streptococcal neonatal disease revisited. The DEVANI European project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Group B streptococcal disease in UK and Irish infants younger than 90 days

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Prevention of group B streptococcal neonatal disease. A plea for a European consensus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Group B streptococci causing neonatal infections in barcelona are a stable clonal population: 18-year surveillance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Emergence and global dissemination of host-specific Streptococcus agalactiae clones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Capsular switching in group B Streptococcus CC17 hypervirulent clone: a future challenge for polysaccharide vaccine development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Distribution of pilus islands in Streptococcus agalactiae that cause human infections: insights into evolution and implication for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

First molecular characterization of group B streptococci with reduced penicillin susceptibility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

High rates of perinatal group B Streptococcus clindamycin and erythromycin resistance in an upstate New York hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Invasive group B streptococcal infections in adults, France (2007–2010)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Molecular characterization of erythromycin-resistant Streptococcus agalactiae strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Prevalence and mechanisms of erythromycin resistance in Streptococcus agalactiae from healthy pregnant women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Invasive neonatal GBS infections from an area-based surveillance study in Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Erythromycin and clindamycin resistance in group B streptococcal clinical isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B streptococcus isolates from Ontario, Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Prevalence and mechanisms of erythromycin resistance in group A and group B Streptococcus: implications for reporting susceptibility results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Antibiotic resistance patterns in invasive group B streptococcal isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Changing molecular epidemiology of group B streptococcus in Korea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

The prevalence of erythromycin resistance in group B streptococcal isolates at a University Hospital in Taiwan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Antimicrobial resistance in colonizing group B Streptococci before the implementation of a Swedish intrapartum antibiotic prophylaxis program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

A new phenotype of resistance to lincosamide and streptogramin A-type antibiotics in Streptococcus agalactiae in New Zealand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Multiple-Clones of Streptococcus agalactiae harbouring lnuB gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

New lnu(C) gene conferring resistance to lincomycin by nucleotidylation in Streptococcus agalactiae UCN36

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Distribution of serotypes and antimicrobial resistance genes among Streptococcus agalactiae isolates from bovine and human hosts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

First Streptococcus agalactiae isolates highly resistant to quinolones, with point mutations in gyrA and parC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

High frequency of fluoroquinolone- and macrolide-resistant streptococci among clinically isolated group B streptococci with reduced penicillin susceptibility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Nosocomial spread of multidrug-resistant group B streptococci with reduced penicillin susceptibility belonging to clonal complex 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Whole-genome shotgun sequencing of a colonizing multilocus sequence type 17 Streptococcus agalactiae strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Prevención de la infección perinatal por estreptococo del grupo B. Recomendaciones españolas. Actualización 2012. Documento de consenso SEIMC/SEGO/SEN/SEQ/SEMFYC

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Neonatal group B streptococcal infection: incidence and strategies for prevention in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Group B streptococcus in the antenatal clinic and in the delivery room: a matter of systematic attitude

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Cost and effectiveness of intrapartum group B streptococcus polymerase chain reaction screening for term deliveries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Ampicillin for neonatal group B streptococcal prophylaxis: how rapidly can bactericidal concentrations be achieved?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Duration of intrapartum prophylaxis for neonatal group B streptococcal disease: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Duration of intrapartum prophylaxis and concentration of penicillin G in fetal serum at delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Optimal timing of ampicillin administration to pregnant women for establishing bactericidal levels in the prophylaxis of Group B Streptococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Rectal Colonization with Group B Streptococcus: Relation to Vaginal Colonization of Pregnant Women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Anorectal and vaginal carriage of group B streptococci during pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Specimen storage in transport medium and detection of group B streptococci by culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Prevention of neonatal group B streptococcal sepsis: is routine antenatal screening appropriate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

The accuracy of late antenatal screening cultures in predicting genital group B streptococcal colonization at delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Comparative evaluation of Strepto B ID chromogenic medium and Granada media for the detection of Group B streptococcus from vaginal samples of pregnant women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Multicenter study of a rapid molecular-based assay for the diagnosis of group B Streptococcus colonization in pregnant women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Intrapartum tests for group B streptococcus: accuracy and acceptability of screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Prevention of perinatal group B streptococcal infection: current controversies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Effects of intrapartum antimicrobial prophylaxis for prevention of group-B-streptococcal disease on the incidence and ecology of early-onset neonatal sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Antibiotic prophylaxis and non-group B streptococcal neonatal sepsis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Influence of antibiotic exposure in the early postnatal period on the development of intestinal microbiota.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Early-onset group B streptococcal disease in the era of maternal screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Group B streptococcal conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Vaccination against group B streptococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Group B streptococcal conjugate vaccine: a timely concept for which the time has come

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Glycoconjugate vaccines to prevent group B streptococcal infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Population-based active surveillance for neonatal group B streptococcal infections in Alberta, Canada: implications for vaccine formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Immunization with C5a peptidase or peptidase-type III polysaccharide conjugate vaccines enhances clearance of group B Streptococci from lungs of infected mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Protection from group B streptococcal infection in neonatal mice by maternal immunization with recombinant Sip protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Identification of a universal Group B streptococcus vaccine by multiple genome screen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Pilus Backbone Contributes to Group BStreptococcusParacellular Translocation through Epithelial Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Specific involvement of pilus type 2a in biofilm formation in group B Streptococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

New Granada Medium for detection and identification of group B streptococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.012

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2013.05.012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23973345%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference